16th Aug 2005 11:15
16 August 2005Shire Pharmaceuticals Group plc (the "Company")Notification of Acquisition of American Depositary Shares by PersonsDischarging Managerial ResponsibilitiesThe Company announces that on 15 August 2005 Mr Matthew Emmens, Chief ExecutiveOfficer of the Company, acquired 5670 American depositary receipts,representing 17,010 ordinary shares of ‚£0.05 each in the Company. 5470 Americandepositary receipts were acquired at a price of $35.24 per American depositaryreceipt and 200 American depositary receipts were acquired at a price of $35.23per American depositary receipt. The Company was notified of this acquisitionon 15 August 2005. As a result of this transaction, Mr Emmens has a totalinterest in 17,010 ordinary shares in the Company.This notification was provided to the Company in satisfaction of Mr Emmens'obligations under sections 324 to 328 of the Companies Act 1985 and DisclosureRule 3.1.2 promulgated by the Financial Services Authority.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), and renal diseases. Shirehas operations in the world's key pharmaceutical markets (US, Canada, UK,France, Italy, Spain and Germany) as well as a specialist drug delivery unit inthe US.For further information on Shire, please visit the Company's website: www.shire.com.Page 2 of 1Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire